|The full article is available to subscribers||Subscriber Login|
Obeticholic acid (Ocaliva – Intercept), a farnesoid X receptor agonist, has been approved by the FDA for treatment of primary biliary cholangitis; it is indicated for use in combination with ursodeoxycholic acid (ursodiol, UDCA; Urso, and others) in adults with an inadequate response to UDCA and as monotherapy in adults unable to tolerate UDCA. Obeticholic acid is the second drug to be approved for this indication; UDCA was the first.
PRIMARY BILIARY CHOLANGITIS — Primary biliary cholangitis, formerly called primary biliary cirrhosis, is a rare progressive autoimmune disease of the intralobular bile ducts that can lead to fibrosis, cirrhosis, and liver failure.1 It most commonly affects women >40 years old.
STANDARD TREATMENT — UDCA, a naturally occurring hydrophilic bile acid, replaces toxic hydrophobic bile acids that accumulate... more
- PJ Trivedi et al. Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Rev Clin Pharmacol 2016; 9:13.
- YQ Huang. Recent advances in the diagnosis and treatment of primary biliary cholangitis. World J Hepatol 2016; 8:1419.
- WJ Lammers et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147:1338.
- F Nevens et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375:631.
- GM Hirschfield et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148:751.
- KV Kowdley et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol 2011; 54:S13 abstract 28.
- Inhibitors and inducers of CYP enzymes and p-glycoprotein. Med Lett Drugs Ther 2017. March 27 (epub). Available at: medicalletter. org/TML-article-1517f. Accessed March 16, 2017.